Strategic Communication and Public Relations

CTS EVENTIM supports German Cancer Research Centre with one million Euro for an endowed chair

No. 18 | 06/05/2015

CTS EVENTIM, Europe’s biggest provider of ticketing services, will finance an endowed chair in ‘Epigenetic Regulation’ at the German Cancer Research Centre (Deutsches Krebsforschungszentrum – DKFZ). The company will donate a total of one million Euro over a five-year period, according to a recent agreement concluded by Klaus-Peter Schulenberg, CEO of CTS EVENTIM, and the Management Board of the DKFZ.

Klaus-Peter Schulenberg, CEO CTS EVENTIM
© Yan de Andres/DKFZ

Our paramount aim in giving this financial support is to help in the important struggle against cancer. Supporting cutting-edge research in Germany is also close to our heart. The DKFZ’s outstanding work makes it an ideal partner for both these concerns’, says Klaus-Peter Schulenberg about his company’s commitment.

‘We are delighted that the generous endowment by CTS EVENTIM will allow us to give a brilliant young talent the opportunity of taking up a chair at our centre’, says Professor Otmar D. Wiestler, Chairman of the Management Board of the German Cancer Research Centre. ‘In a joint effort with the University of Heidelberg, we shall initiate an appointment procedure very soon so that a highly qualified candidate is recruited as quickly as possible.’

In their search, the DKFZ and the university will focus on young talents with an innovative and original research approach, with which they can also compete at international level.

‘Cutting-edge research costs a lot of money, so even when it is supported by the public sector it is reliant more than ever before on support from private-sector donors’, says Professor Josef Puchta, the Administrative and Commercial Director of the German Cancer Research Centre. ‘Sourcing private-sector money for research is still uncommon in Germany. In the USA or Israel, in contrast, there is a strong tradition of supporting research in this way. Our hope is therefore that the wonderful example set by CTS EVENTIM will be emulated by very many others’, says Puchta. 

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS